Long-Term Cabozantinib/Nivolumab Data Show Improved Survival in RCC
Manojkumar Bupathi, MD, MS, discusses the updated efficacy results of the CheckMate 9ER trial of cabozantinib plus nivolumab for patients with previously untreated advanced clear cell renal cell carcinoma.